Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00 2022-09-23 pm EDT
166.72 USD   +0.32%
09/22US Stocks End Lower Thursday Despite Healthcare Gains
MT
09/22US Stocks End Lower Thursday Despite Surge in Healthcare Shares
MT
09/22Johnson & Johnson - Diversifying Our Health Workforce through the Impact of AIM
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : Consumer Health to Transition Global Baby Powder Portfolio to Cornstarch

08/11/2022 | 05:22pm EDT

August 11, 2022 - "As part of a worldwide portfolio assessment, we havemade the commercial decision to transition to an all cornstarch-based baby powder portfolio. As a result of this transition, talc-based JOHNSON'S® Baby Powder will be discontinued globally in 2023.

We continuously evaluate and optimize our portfolio to best position the business for long-term growth. This transition will help simplify our product offerings, deliver sustainable innovation, and meet the needs of our consumers, customers and evolving global trends.

Cornstarch-based JOHNSON'S® Baby Powder is already sold in countries around the world. JOHNSON'S® is a flagship global brand of Johnson & Johnson Consumer Health and we remain fully committed to ensuring JOHNSON'S® products are loved by parents and families for years to come.

Our position on the safety of our cosmetic talc remains unchanged. We stand firmly behind the decades of independent scientific analysis by medical experts around the world that confirms talc-based JOHNSON'S® Baby Powder is safe, does not contain asbestos, and does not cause cancer."

Disclaimer

Johnson & Johnson published this content on 11 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 August 2022 21:17:16 UTC.


© Publicnow 2022
All news about JOHNSON & JOHNSON
09/22US Stocks End Lower Thursday Despite Healthcare Gains
MT
09/22US Stocks End Lower Thursday Despite Surge in Healthcare Shares
MT
09/22Johnson & Johnson - Diversifying Our Health Workforce through the Impact of AIM
AQ
09/22Over 200 Inmates, Prison Officers Vaccinated Against Covid-19
AQ
09/21J&J's talc Texas two-step called out by victims
AQ
09/20No, Covid Vaccines Don't Cause Body to Produce Toxic Spike Proteins That Cause Cancer
AQ
09/20Johnson & Johnson Sets Up New R&D Facility in San Francisco Bay Area
MT
09/20Johnson & Johnson Opens State-of-the-Art Science and Technology Campus in San Francisco..
BU
09/20Johnson & Johnson Opens New R&D Facility in San Francisco Bay Area
DJ
09/19JOHNSON & JOHNSON : Debuts a Groundbreaking R&D Facility in the San Francisco Bay Area
PU
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 525 M - -
Net income 2022 22 023 M - -
Net cash 2022 9 791 M - -
P/E ratio 2022 20,4x
Yield 2022 2,62%
Capitalization 438 B 438 B -
EV / Sales 2022 4,49x
EV / Sales 2023 4,20x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 166,72 $
Average target price 185,07 $
Spread / Average Target 11,0%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-2.54%438 337
ELI LILLY AND COMPANY12.76%295 941
ROCHE HOLDING AG-18.41%259 291
ABBVIE INC.5.66%252 944
PFIZER, INC.-25.35%247 392
NOVO NORDISK A/S1.95%221 838